Display Settings:

Format

Send to:

Choose Destination
    Cancer Immunol Immunother. 2004 Feb;53(2):64-72. Epub 2003 Oct 30.

    Derangement of immune responses by myeloid suppressor cells.

    Source

    Department of Oncology and Surgical Sciences, Oncology Section, Azienda Ospedaliera, Via Gattamelata 64, 35128, Padova, Italy.

    Abstract

    In tumor-bearing mice and cancer patients, tumor progression is often associated with altered hematopoiesis leading to the accumulation of myeloid cells. Extensive studies in preclinical models indicate that these cells share the CD11b and the Gr-1 markers, possess a mixed mature-immature myeloid phenotype, and are responsible for the induction of T-cell dysfunctions, both tumor-specific and nonspecific. Moreover, CD11b(+)Gr-1(+) myeloid cells are described under different unrelated situations associated with temporary impairment of the T-lymphocyte reactivity. This review examines recent findings on the nature, properties, and mechanisms of action of these myeloid suppressor cells (MSCs).

    PMID:
    14593498
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Springer

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk